
Quarterly report 2024-Q1
added 05-06-2024
ShockWave Medical Revenue 2011-2026 | SWAV
Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.
Traditionally defined as follows:Revenue = Price * Quantity of productsRevenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]
This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.
Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.
Annual Revenue ShockWave Medical
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 730 M | 490 M | 237 M | 67.8 M | 42.9 M | 12.3 M | 1.72 M | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 730 M | 1.72 M | 226 M |
Quarterly Revenue ShockWave Medical
| 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 219 M | 186 M | 180 M | 161 M | - | 131 M | 121 M | 93.6 M | - | 65.2 M | 55.9 M | 31.9 M | - | 19.6 M | 10.3 M | 15.2 M | - | 11.3 M | 10 M | 7.27 M | - | 3.6 M | 2.28 M | 1.32 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 219 M | 1.32 M | 69.8 M |
References
- Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).
Revenue of other stocks in the Medical devices industry
| Issuer | Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
EDAP TMS S.A.
EDAP
|
44.1 M | $ 3.22 | -2.57 % | $ 121 M | ||
|
Align Technology
ALGN
|
4 B | $ 189.61 | -0.56 % | $ 14.2 B | ||
|
Axonics Modulation Technologies
AXNX
|
274 M | - | - | $ 3.31 B | ||
|
Aziyo Biologics
AZYO
|
12.3 M | - | 1.37 % | $ 20.5 M | ||
|
GenMark Diagnostics, Inc.
GNMK
|
172 M | - | - | $ 1.77 B | ||
|
Avinger
AVGR
|
7.65 M | - | -20.74 % | $ 369 K | ||
|
AdaptHealth Corp.
AHCO
|
3.24 B | $ 12.8 | 0.55 % | $ 1.73 B | ||
|
BIOLASE
BIOL
|
49.2 M | - | -13.19 % | $ 166 K | ||
|
Allied Healthcare Products
AHPI
|
6.02 M | - | 3.58 % | $ 2.21 M | ||
|
BioSig Technologies
BSGM
|
40 K | - | 37.08 % | $ 85.7 M | ||
|
Obalon Therapeutics, Inc.
OBLN
|
1.59 M | - | -5.86 % | $ 30.6 M | ||
|
Conformis
CFMS
|
62 M | - | - | $ 16.4 M | ||
|
Helius Medical Technologies
HSDT
|
644 K | $ 2.16 | 4.85 % | $ 1.31 M | ||
|
Cardiovascular Systems
CSII
|
236 M | - | 0.15 % | $ 844 M | ||
|
Cytosorbents Corporation
CTSO
|
37.1 M | $ 0.63 | -3.04 % | $ 39.2 M | ||
|
Apollo Endosurgery
APEN
|
76.9 M | - | - | $ 475 M | ||
|
OrthoPediatrics Corp.
KIDS
|
236 M | $ 16.19 | -0.12 % | $ 380 M | ||
|
ClearPoint Neuro
CLPT
|
37 M | $ 11.78 | 9.58 % | $ 334 M | ||
|
LivaNova PLC
LIVN
|
1.39 B | $ 64.2 | -1.45 % | $ 3.5 B | ||
|
Dynatronics Corporation
DYNT
|
27.4 M | - | 14.99 % | $ 929 K | ||
|
Eargo
EAR
|
37.2 M | - | - | $ 10.2 M | ||
|
Pulmonx Corporation
LUNG
|
90.5 M | $ 1.27 | -0.78 % | $ 51.7 M | ||
|
CryoLife, Inc.
CRY
|
253 M | - | -4.14 % | $ 702 M | ||
|
Electromed
ELMD
|
64 M | $ 26.39 | 3.57 % | $ 223 M | ||
|
Second Sight Medical Products
EYES
|
1 K | - | -0.97 % | $ 54.4 M | ||
|
Hancock Jaffe Laboratories, Inc.
HJLI
|
4.25 K | - | -1.98 % | $ 98.3 M | ||
|
Itamar Medical Ltd.
ITMR
|
41 M | - | 0.03 % | $ 1.58 B | ||
|
GBS
GBS
|
3.05 M | - | -0.57 % | $ 7.12 M | ||
|
Misonix, Inc.
MSON
|
62.5 M | - | - | $ 462 M | ||
|
Neovasc
NVCN
|
2.55 M | - | - | $ 111 M | ||
|
Globus Medical
GMED
|
2.94 B | $ 94.87 | 0.52 % | $ 12.8 B | ||
|
Orthofix Medical
OFIX
|
822 M | $ 12.35 | 1.65 % | $ 489 M | ||
|
Butterfly Network
BFLY
|
82.1 M | $ 5.33 | 3.5 % | $ 1.13 B | ||
|
Intersect ENT, Inc.
XENT
|
80.6 M | - | - | $ 955 M | ||
|
Delcath Systems
DCTH
|
85.2 M | $ 10.84 | 1.88 % | $ 388 M | ||
|
IRIDEX Corporation
IRIX
|
52.7 M | $ 1.06 | 0.95 % | $ 18 M | ||
|
Insulet Corporation
PODD
|
2.71 B | $ 189.56 | -1.38 % | $ 13.3 B | ||
|
CONMED Corporation
CNMD
|
1.37 B | $ 38.34 | 2.24 % | $ 1.19 B | ||
|
Inspire Medical Systems
INSP
|
912 M | $ 56.31 | -0.07 % | $ 1.65 B | ||
|
Integer Holdings Corporation
ITGR
|
1.85 B | $ 86.02 | 1.37 % | $ 2.99 B | ||
|
PAVmed
PAVM
|
71 K | $ 9.0 | -1.85 % | $ 6.03 M | ||
|
Invacare Corporation
IVC
|
181 M | - | - | $ 24.7 M | ||
|
Edwards Lifesciences Corporation
EW
|
6.07 B | $ 84.15 | 5.56 % | $ 49.2 B | ||
|
LENSAR
LNSR
|
58.4 M | $ 5.09 | -3.23 % | $ 60.9 M | ||
|
Sintx Technologies
SINT
|
1.02 M | $ 2.47 | -1.59 % | $ 6.85 M | ||
|
MiMedx Group
MDXG
|
419 M | $ 3.43 | 2.39 % | $ 507 M | ||
|
Stryker Corporation
SYK
|
7.17 B | $ 327.51 | -0.65 % | $ 125 B |